Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer

Trastuzumab has significantly improved the overall survival of patients with HER2+ metastatic breast cancer (MBC). However, outcomes can vary, with patients progressing within 1 year of treatment or exceptional cases of complete response to trastuzumab for ≥10 years. Identification of the underlying...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Naomi, Andrieu, Charlotte, O’Donovan, Peter, Quinn, Cecily, Maguire, Alanna, Furney, Simon J., Gullo, Giuseppe, Crown, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553955/
https://www.ncbi.nlm.nih.gov/pubmed/32713940
http://dx.doi.org/10.1038/s41416-020-0999-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553955/
https://www.ncbi.nlm.nih.gov/pubmed/32713940
http://dx.doi.org/10.1038/s41416-020-0999-z

Ejemplares similares